Latest News

As global markets continue to navigate a complex landscape, U.S. stocks have shown resilience by rallying at the start of the year, with small-cap and value shares leading the charge. In this context, penny stocks—often overlooked yet still significant—represent an intriguing investment area for those seeking growth opportunities in smaller or newer companies. Despite being considered a niche market, these stocks can offer substantial returns when backed by robust financial health. Let's...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...

Key Insights Insiders appear to have a vested interest in Blau Farmacêutica's growth, as seen by their sizeable...

As 2026 begins, global markets have shown resilience with U.S. stocks rallying to new highs despite geopolitical tensions, and small-cap shares leading the charge with impressive gains in indices like the Russell 2000. Amid these dynamic conditions, identifying promising stocks involves looking for companies that can capitalize on unique opportunities within sectors poised for growth or those that demonstrate strong fundamentals and adaptability in a changing economic landscape.

There wouldn't be many who think Jalles Machado S/A's ( BVMF:JALL3 ) price-to-sales (or "P/S") ratio of 0.4x is worth a...

As global markets kick off the year with strong performances, investors are navigating a landscape marked by geopolitical tensions and mixed economic signals. Amidst these dynamics, dividend stocks have garnered attention for their potential to offer steady income streams, especially in times of market volatility. In this environment, selecting dividend stocks that balance yield with stability can be an effective strategy for investors seeking consistent returns.

With a price-to-earnings (or "P/E") ratio of 13.1x SLC Agrícola S.A. ( BVMF:SLCE3 ) may be sending bearish signals at...

Lundin Gold (TSX:LUG) has drawn fresh attention after reporting 2025 operating results at its Fruta del Norte mine, meeting production guidance while processing record ore with higher recoveries and outlining operational targets for 2026. See our latest analysis for Lundin Gold. The production update comes after a strong run in the shares, with a 30 day share price return of 9.14% and a 1 year total shareholder return of over 2.7x. This suggests momentum has been building as investors...

Recent coverage has highlighted how ownership concentration and broad shareholder participation at Northern Minerals is shaping governance and strategic influence in its long‑dated mining projects. This focus on who holds power in the register offers investors a clearer view of how decisions may be made and aligned across stakeholders. Next, we examine how this growing interest in Northern Minerals’ ownership structure could influence the company’s broader investment narrative. Uncover the...

Why EZCORP’s latest earnings and rating shift matter for investors EZCORP (EZPW) recently reported quarterly earnings that exceeded analyst expectations, coinciding with a move from a “strong-buy” to “buy” rating at one research outlet while other brokerages kept positive views in place. This combination of strong results and a modest rating change gives you a fresh data point to consider when assessing how the pawn-focused lender’s current share price compares with its recent performance and...

Earlier in January 2026, Alumis Inc. reported positive topline Phase 3 ONWARD1 and ONWARD2 results for its oral TYK2 inhibitor envudeucitinib in moderate-to-severe plaque psoriasis and subsequently completed a US$300.05 million follow-on common stock offering at US$17.00 per share. A key angle for investors is how envudeucitinib’s differentiated clinical profile and “pipeline-in-a-pill” potential, including possible applications in systemic lupus erythematosus, could influence Alumis’s...

In early January 2026, Caris Life Sciences announced a partnership with digital health company Everlywell to launch Caris Detect, a multi-cancer early detection blood test that applies whole genome sequencing and AI to identify molecular signals of cancer in the bloodstream, with commercialization planned through Everlywell’s platform in the first half of 2026. This collaboration highlights how advanced genomic screening and consumer-focused digital health distribution could broaden access...

Recently, two senior Robert Half executives, Paul F. Gentzkow and George Denlinger, were named to Staffing Industry Analysts’ 2026 North America Staffing 100 list, recognizing their long-term leadership in talent and consulting services. This industry recognition, alongside commentary about resilient consulting operations and easing macroeconomic pressures, highlights how management strength may support Robert Half’s positioning in a gradually improving staffing landscape. We’ll now examine...

Alexandria Real Estate Equities (ARE) is back in focus after investors filed multiple securities class action lawsuits related to its Long Island City property, following weaker than expected 2025 results and a large impairment charge. See our latest analysis for Alexandria Real Estate Equities. The latest legal actions and impairment news come after a volatile stretch where the share price return has recently improved, with a 30 day share price return of 18.41% and year to date share price...

If you are wondering whether Asana's current share price reflects its true worth, you are not alone. This article focuses squarely on what the numbers say about value. At a last close of US$11.42, the stock has seen a 15.7% decline over the past week, a 19.2% decline over the past month, an 11.9% decline year to date, and a 41.9% decline over the past year, with a 71.1% decline over five years and an 18.7% decline over three years. Recent attention on Asana has centered on how its work...

argenx SE recently announced that the FDA has accepted for priority review a supplemental Biologics License Application for VYVGART to treat adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis, supported by Phase 3 ADAPT SERON data showing statistically significant improvements in daily living scores versus placebo. This priority review, with a PDUFA action date set for May 10, 2026, could materially broaden VYVGART’s reach across previously underserved...

If you are wondering whether BASF at €45.82 is a bargain or just fairly priced, it helps to break the story down into what the recent share moves and valuation checks are actually saying. Over the short term, BASF shares have returned 3.8% over 7 days, 3.5% over 30 days and 2.3% year to date, while the 1 year return sits at 9.0% and the 3 year return at 4.8%. This compares with a 5 year return of a 7.0% decline. Recent news around BASF has focused on its role as a major European chemicals...

If you are wondering whether Viavi Solutions at around US$17.80 is still good value after a strong run, you are not alone. The stock has pulled back 4.0% over the last week and is slightly lower over the past month and year to date, yet it is still up 75.5% over 1 year and 59.8% over 3 years, with a 5 year return of 9.7%. Recently, news flow around Viavi Solutions has focused on its role as a provider of network testing and monitoring equipment, particularly for telecoms and data center...

What triggered the latest move in IperionX? IperionX (ASX:IPX) is back on investor radars after securing a U.S. Department of Defense contract valued at up to US$99 million, tied to domestic titanium production for defense uses. See our latest analysis for IperionX. The stock’s recent move sits within a mixed backdrop, with a 1 month share price return of 40.36% and a year to date share price return of 20.73%. The 1 year total shareholder return of 58.14% and very large 5 year total...

If you are wondering whether IMAX at around US$35.07 is still good value after its run, this article will walk through what the current share price might be implying. The stock has had a mixed run recently, with a 2.8% gain over the last week, a 10.2% decline over the last month, and returns of 54.0% over 1 year, 120.6% over 3 years, and 88.3% over 5 years. Recent attention on IMAX has centered on box office trends and its position in premium large format cinema, as investors assess how...

Context for ServiceNow’s recent share performance ServiceNow (NOW) has been under pressure recently, with the stock showing a 2.6% decline over the past day, a 10.8% drop over the past week, and deeper losses over the past month and past 3 months. See our latest analysis for ServiceNow. Zooming out, ServiceNow’s recent share price weakness, including the 1 year total shareholder return of 36.15% in the red and the year to date share price return of 8.71% in the red, points to fading momentum...

Why a Panama LNG lawsuit has put AES (AES) under the spotlight A new civil lawsuit in Virginia, accusing AES (AES) of working with partners to exclude Sinolam from Panama’s LNG to power market and seeking over US$4b in damages, has sharply focused investor attention. See our latest analysis for AES. At a share price of US$14.00, AES has a year to date share price return of a 5.53% decline, while the 1 year total shareholder return of 26.25% contrasts with a 3 year total shareholder return of...

If you are wondering whether Lamar Advertising at around US$130.78 is offering fair value today, you are not alone. This article will walk through what that price really buys you as an investor. The stock has recently posted returns of 2.8% over 7 days, 3.0% over 30 days, 5.4% year to date, 15.5% over 1 year, 50.2% over 3 years and 97.4% over 5 years, so recent performance is front of mind for many holders. Recent headlines around Lamar Advertising have mainly focused on its position in the...

What recent performance says about Watsco (WSO) Without a specific news headline driving attention today, Watsco (WSO) is drawing interest after a mixed run for shareholders, with a 1 day decline, solid recent gains, and a weaker past year overall. See our latest analysis for Watsco. At a share price of $372.51, Watsco has paired a 7 day share price return of 6.6% and a 1 month share price return of 8.1% with a weaker 1 year total shareholder return of 20.2% and stronger multi year gains...